Loading...
By Kristin J. Kelley
Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS
The FDA has given the go-ahead for the genetics testing company 23andMe to market the first direct-to-consumer test that can assess if a person has genetic variants that may affect their ability to metabolize certain drugs.
The 23andMe Personal Genome Service Pharmacogenetic Reports, which use self-collected saliva samples to analyze DNA, detect 33 genetic variants. The FDA warns that the test doesn't diagnose conditions or determine whether a patient should be taking a certain drug.
The agency cautions: "Health care providers should not use the test to make any treatment decisions. Results from this test should be confirmed with independent pharmacogenetic testing before making any medical decisions."
Comment
LINK(S):
FDA news release (Free)
Background: Physician's First Watch coverage of FDA clearing 23andMe BRCA mutations test (Free)